| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 258.087 | 316.028 | 8.106 | 13.063 |
| Total Income - EUR | - | - | - | - | - | - | 258.087 | 317.279 | 8.569 | 13.063 |
| Total Expenses - EUR | - | - | - | - | - | - | 160.570 | 282.600 | 29.075 | 33.604 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 97.517 | 34.678 | -20.507 | -20.541 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 94.987 | 31.886 | -20.586 | -20.541 |
| Employees | - | - | - | - | - | - | 7 | 10 | 4 | 1 |
Check the financial reports for the company - Placebo Meds S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 7.292 | 25.395 | 21.696 | 11.923 |
| Current Assets | - | - | - | - | - | - | 106.321 | 19.400 | 7.212 | 4.852 |
| Inventories | - | - | - | - | - | - | 7.368 | 1.330 | 0 | 0 |
| Receivables | - | - | - | - | - | - | 1.044 | 12.746 | 6.318 | 4.541 |
| Cash | - | - | - | - | - | - | 97.909 | 5.324 | 895 | 311 |
| Shareholders Funds | - | - | - | - | - | - | 95.028 | 32.309 | 11.624 | -8.981 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 18.585 | 13.688 | 17.284 | 25.756 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Placebo Meds S.r.l.